Fungal Infections
Conditions
Keywords
fungal infections, SARS-CoV-2, pandemic, post-pandemic
Brief summary
his study aims to retrospectively compare fungal positivity rates between the SARS-CoV-2 pandemic and the post-pandemic periods. During the pandemic, Candida species had a positivity rate of 17.36%, and Aspergillus had a rate of 2.22%. Post-pandemic, these rates decreased to 9.29% and 1.00%, respectively. The overall fungal positivity rate decreased from 9.15% during the pandemic to 5.13% post-pandemic. Statistical analysis revealed a significant decrease in fungal positivity rates post-pandemic (p \< 0.01). These findings underscore the effectiveness of post-pandemic healthcare interventions and infection control strategies.
Detailed description
The study aims to retrospectively compare fungal positivity rates by focusing on Candida and Aspergillus species during the SARS-CoV-2 pandemic and in the post-pandemic period. The dataset includes samples collected during the pandemic period (N=623) and the subsequent post-pandemic period (N=818). Fungal positivity rates were calculated and statistically analyzed using chi-square tests, and significance was determined as p\<0.01. During the SARS-CoV-2 pandemic, Candida species showed a positivity rate of 17.36%, while the rate in the post-pandemic period significantly decreased to 9.29% (p=0.002). In contrast, Aspergillus species did not show a significant change in positivity rates between the pandemic (2.22%) and post-pandemic (1.00%) periods (p=0.186, NS). Overall, the study provides valuable insights into the epidemiology of fungal infections during and after the SARS-CoV-2 pandemic, suggesting possible shifts in fungal pathogen prevalence and healthcare priorities. The findings contribute to the development of targeted healthcare strategies and surveillance measures for fungal infections in the post-pandemic era. Study Design: Retrospective comparative analysis Data Analysis: Chi-square tests, p\<0.01 considered significant
Interventions
DIAGNOSTIC_TESTCulture, İsolation
Data on patient demographics, clinical conditions, and fungal infection positivity rates were extracted from hospital records. Fungal positivity rates were calculated based on laboratory results and presented as percentages. Statistical analyses were performed using the Chi-Square test, and p-values were reported.
Sponsors
Bekir Sami Uyanık
Study design
Observational model
OTHER
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
Patients over 18 years of age of both genders
Exclusion criteria
* Patients under 18 years of age, * Patients whose demographic, clinical and laboratory data investigated in the study could not be accessed, patients who were diagnosed with fungal infection during hospitalization
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Fungal positivity rates during the SARS-CoV-2 pandemic period and post-pandemic period | 2020-2024 | Fungal infection data from samples of patients, 623 of whom were during the SARS-CoV-2 epidemic and 818 of whom were in the post-epidemic period, were retrospectively examined. Fungal positivity rates for different fungal agents such as Candida species and Aspergillus were calculated separately and compared statistically. |
Countries
Turkey (Türkiye)
Outcome results
None listed